1. Syed AT, Lone NA, Wani MA, Bhat AS. Clinical management of patients with minor head injuries. Int J Health Sci (Qassim). 2007;1(1):131-140.
2. Goldstein M. Traumatic brain injury: a silent epidemic. Ann Neurol. 1990;27(3):327. doi:10.1002/ana.410270315
3. Yusuf AS, Odebode TO, Adeniran JO, et al. Pattern and outcome of motorcyclists head injury in Ilorin, Nigeria. Niger J Basic Clin Sci. 2014; 11(2):80-84. doi:10.4103/0331-8540.140340
4. Emejulu JKC, Isiguzo CM, Agbasoga CE, Ogbuagu CE. Traumatic brain injury in the accident and emergency department of a tertiary hospital in Nigeria. East Cent Africa J Surg. 2010;15(2):28-38.
5. Adeleye AO. Pattern of referrals of head injury to the University College Hospital, Ibadan. Ann Ibadan Postgrad Med. 2017;15(1):34-40.
6. Adeolu AA, Malomo AO, Shokunbi MT, Komolafe EO, Abiona TC. Etiology of head injuries in southwestern Nigeria: a public health perspective. Internet J Epidemiol. 2004;2(2):10-13. doi:10.5580/21d2
7. Ismail NJ, Lasseini A. Management of intracranial epidural haematoma. J Dent Med Sci. 2020;19(3):51-55. doi:10.9790/0853-1903165155
8. Mattei TA, Teasdale GM. The story of the development and adoption of the Glasgow Coma Scale: part I, the early years. World Neurosurg. 2020; 134:311-322. doi:10.1016/j.wneu.2019.10.193
9. Galgano M, Toshkezi G, Qiu X, Russell T, Chin L, Zhao LR. Traumatic brain injury: current treatment strategies and future endeavors. Cell Transplant. 2017;26(7):1118-1130. doi:10.1177/0963689717714102
10. Opondo EA, Mwangombe NJM. Outcome of severe traumatic brain injury at a critical care unit: a review of 87 patients. Ann African Surg. 2009;1(1):3-9. doi:10.4314/aas.v1i1.45788
11. Gaddam SSK, Buell T, Robertson CS. Systemic manifestations of traumatic brain injury. Handb Clin Neurol. 2015;127:205-218. doi:10. 1016/B978-0-444-52892-6.00014-3
12. Ma Q, Xing C, Long W, Wang HY, Liu Q, Wang R-F. Impact of microbiota on central nervous system and neurological diseases: the gut-brain axis. J Neuroinflammation. 2019;16(1):53. doi:10.1186/s12974-019-1434-3
13. Zhu CS, Grandhi R, Patterson TT, Nicholson SE. A review of traumatic brain injury and the gut microbiome: insights into novel mechanisms of secondary brain injury and promising targets for neuroprotection. Brain Sci. 2018;8(6):1-13. doi:10.3390/brainsci8060113
14. Rice MW, Pandya JD, Shear DA. Gut microbiota as a therapeutic target to ameliorate the biochemical, neuroanatomical, and behavioral effects of traumatic brain injuries. Front Neurol. 2019;10(8):1-8. doi:10.3389/fneur.2019.00875
15. Kaur P, Sharma S. Recent advances in pathophysiology of traumatic brain injury. Curr Neuropharmacol. 2017;16(8):1224-1238. doi:10.2174/1570159x15666170613083606
16. Han Y, Wang B, Gao H, et al. Vagus nerve and underlying impact on the gut microbiota-brain axis in behavior and neurodegenerative diseases. J Inflamm Res. 2022;15:6213-6230. doi:10.2147/JIR.S384949
17. Galland L. The gut microbiome and the brain. J Med Food. 2014;17(12): 1261-1272. doi:10.1089/jmf.2014.7000
18. Dickerson RN, Mitchell JN, Morgan LM, et al. Disparate response to metoclopramide therapy for gastric feeding intolerance in trauma patients with and without traumatic brain injury. JPEN J Parenter Enteral Nutr. 2009;33(6):646-655. doi:10.1177/0148607109335307
19. Lin D, Howard A, Raihane AS, et al. Traumatic brain injury and gut microbiome: the role of the gut-brain axis in neurodegenerative processes. Curr Neurol Neurosci Rep. 2025;25(1):23. doi:10.1007/s11910-025-01410-0
20. Zheng Y, Bonfili L, Wei T, Eleuteri AM. Understanding the gut-brain axis and its therapeutic implications for neurodegenerative disorders. Nutrients. 2023;15:4631. doi:10.3390/nu15214631
21. Jamerlan AM, An SSA, Hulme JP. Microbial diversity and fitness in the gut-brain axis: influences on developmental risk for Alzheimer’s disease. Gut Microbes. 2025;17(1):2486518. doi:10.1080/19490976.2025.2486518
22. Loh JS, Mak WQ, Tan LKS, et al. Microbiota-gut-brain axis and its therapeutic applications in neurodegenerative diseases. Signal Transduct Target Ther. 2024;9(1):37. doi:10.1038/s41392-024-01743-1
23. Ashique S, Mohanto S, Ahmed MG, et al. Gut-brain axis: a cutting-edge approach to target neurological disorders and potential synbiotic application. Heliyon. 2024;10(13):e34092. doi:10.1016/j.heliyon.2024.e34092
24. Dicks LMT. Gut bacteria and neurotransmitters. Microorganisms. 2022;10:1838. doi:10.3390/microorganisms10091838
25. Xu J, Lu Y. The microbiota-gut-brain axis and central nervous system diseases: from mechanisms of pathogenesis to therapeutic strategies. Front Microbiol. 2025;16:1583562. doi:10.3389/fmicb.2025.1583562
26. Alavian F, Safaeian M. How the gut microbiome shapes learning and memory: a comprehensive review. IBRO Neurosci Reports. 2025;19:491-506. doi:10.1016/j.ibneur.2025.08.005
27. Kandpal M, Indari O, Baral B, et al. Dysbiosis of gut microbiota from the perspective of the gut-brain axis: role in the provocation of neurological disorders. Metabolites. 2022;12:1064. doi:10.3390/metabo12111064
28. Lu S, Zhao Q, Guan Y, et al. The communication mechanism of the gut-brain axis and its effect on central nervous system diseases: a systematic review. Biomed Pharmacother. 2024;178:117207. doi:10.1016/j.biopha. 2024.117207
29. Ullah H, Arbab S, Tian Y, et al. The gut microbiota-brain axis in neurological disorder. Front Neurosci. 2023;17:1225875. doi:10.3389/fnins.2023.1225875
30. Mitra S, Dash R, Nishan A Al, Habiba SU, Moon IS. Brain modulation by the gut microbiota: from disease to therapy. J Adv Res. 2023;53:153-173. doi:10.1016/j.jare.2022.12.001
31. Shen Y, Fan N, Ma SX, Cheng X, Yang X, Wang G. Gut microbiota dysbiosis: pathogenesis, diseases, prevention, and therapy. MedComm. 2025;6:e70168. doi:10.1002/mco2.70168
32. Camberos-Barraza J, Guadrón-Llanos AM, De la Herrán-Arita AK. The gut microbiome-neuroglia axis: implications for brain health, inflammation, and disease. Neuroglia. 2024;5:254-273. doi:10.3390/neuroglia5030018
33. Baassiri E, Baassiri MG El, Raouf Z, et al. Dysregulated brain-gut axis in the setting of traumatic brain injury: review of mechanisms and anti-inflammatory pharmacotherapies. J Neuroinflammation. 2024; 21(124):1-31. doi:10.1186/s12974-024-03118-3
34. Lingdi N, Mingchun G, Yifan L, et al. Effects of the stress hormone norepinephrine on the probiotic properties of Levilactobacillus: antibacterial colonization, anti-inflammation, and antioxidation. Front Microbiol. 2025;16:1526362. doi:10.3389/fmicb.2025.1526362
35. Li D, Chen J, Weng C, Huang X. Impact of the severity of brain injury on secondary adrenal insufficiency in traumatic brain injury patients and the influence of HPA axis dysfunction on prognosis. Int J Neurosci. 2024;134(11):1414-1423. doi:10.1080/00207454.2023.2280450
36. Yao H, Yu J, Yang X, Xu J. Ecotoxicology and Environmental Safety Mechanisms of disruption of the gut-brain axis by environmental endocrine disruptors. Ecotoxicol Environ Saf. 2025;304:119124. doi:10. 1016/j.ecoenv.2025.119124
37. Dmytriv TR, Storey KB, Lushchak VI. Intestinal barrier permeability: the influence of gut microbiota, nutrition, and exercise. Front Physiol. 2024;15:1380713. doi:10.3389/fphys.2024.1380713
38. Agrawal H, Agarwal N, Gupta N. Enteric nervous system as a therapeutic target in gastrointestinal disorders.World J Gastrointest Pharmacol Ther. 2025;16(4):110843. doi:10.4292/wjgpt.v16.i4.110843
39. Yu B, Hua B. The interplay between the microbiota and opioid in the treatment of neuropathic pain. Front Microbiol. 2024;15:1390046. doi: 10.3389/fmicb.2024.1390046
40. Zádori ZS, Király K, Al-khrasani M, Gyires K. Interactions between NSAIDs, opioids and the gut microbiota-future perspectives in the management of inflammation and pain. Pharmacol Ther. 2023;241: 108327. doi:10.1016/j.pharmthera.2022.108327
41. Ramirez J, Guarner F, Fernandez LB, Maruy A, Sdepanian VL, Cohen H. Antibiotics as major disruptors of gut microbiota. Front Cell Infect Microbiol. 2020;10:572912. doi:10.3389/fcimb.2020.572912
42. Ling Z, Ding W, Liu X, et al. Gut microbiota dysbiosis and systemic immune dysfunction in critical ill patients with multidrug-resistant bacterial colonization and infection. J Transl Med. 2025;23:981. doi:10. 1186/s12967-025-07049-2
43. Yang W, Yuan Q, Li Z, et al. Translocation and dissemination of gut bacteria after severe traumatic brain injury. Microorganisms. 2022; 10(10):2082. doi:10.3390/microorganisms10102082
44. Kearns R. Gut-brain axis and neuroinflammation: the role of gut permeability and the kynurenine pathway in neurological disorders. Cell Mol Neurobiol. 2024;44:64. doi:10.1007/s10571-024-01496-z
45. Krakovski MA, Arora N, Jain S, et al. Diet-microbiome-gut-brain nexus in acute and chronic brain injury. Front Neurosci. 2022;16:1002266. doi: 10.3389/fnins.2022.1002266
46. Albert V, Kedia S, Subramanian A. A comprehensive review of the brain-gut microbiota system in traumatic brain injury: mechanisms, outcomes, and emerging interventions. Indian J Neurosurg. 2025;14:103-110. doi:10. 1055/s-0045-1806842
47. Hill C, Guarner F, Reid G, et al. Expert consensus document: the international scientific association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11:506-514. doi:10.1038/nrgastro.2014.66
48. Sanders ME. Probiotics: definition, sources, selection, and uses. Clin Infect Dis. 2008;46(Suppl 2):S58-S151. doi:10.1086/523341
49. McFarland L V. From yaks to yogurt: the history, development, and current use of probiotics. Clin Infect Dis. 2015;60(S2):S85-S90. doi:10. 1093/cid/civ054
50. Gogineni VK, Morrow LE, Gregory PJ, Malesker MA. Probiotics: history and evolution. J Anc Dis Prev Remedies. 2013;1:107. doi:10.4172/ 2329-8731.1000107
51. Behnsen J, Deriu E, Sassone-Corsi M, Raffatellu M. Probiotics: properties, examples, and specific applications. Cold Spring Harb Perspect Biol. 2013;5(2):a010074. doi:10.1101/cshperspect.a010074
52. Hemaiswarya S, Raja R, Ravikumar R, Carvalho IS. Mechanism of action of probiotics. Brazilian Arch Biol Technol. 2013;56(1):113-119. doi:10.1590/S1516-89132013000100015
53. Plaza-Diaz J, Ruiz-Ojeda FJ, Gil-Campos M, Gil A. Mechanisms of action of probiotics. Adv Nutr. 2019;10(suppl 1):S49-S66. doi:10.1093/advances/nmy063
54. O’Hara AM, Shanahan F. Mechanisms of action of probiotics in intestinal diseases. ScientificWorldJournal. 2007;7:31-46. doi:10.1100/tsw.2007.26
55. Gogineni VK, Morrow LE. Probiotics: mechanisms of action and clinical applications. J Probiotics Health. 2013;1(1)1-11. doi:10.4172/2329-8901. 1000101
56. Rijkers GT. Probiotics for severe trauma patients. Crit Care. 2011;15: 1022. doi:10.1186/cc10589
57. McFarland LV. Use of probiotics to correct dysbiosis of normal microbiota following disease or disruptive events: a systematic review. Br Med J Open. 2014;4(8):e005047. doi:10.1136/bmjopen-2014-005047
58. Falcão De Arruda IS, De Aguilar-Nascimento JE. Benefits of early enteral nutrition with glutamine and probiotics in brain injury patients. Clin Sci (Lond). 2004;106(3):287-292. doi:10.1042/CS20030251
59. Somashekaraiah R, Shruthi B, Deepthi BV, Sreenivasa MY. Probiotic properties of lactic acid bacteria isolated from neera: a naturally fermenting coconut palm nectar. Front Microbiol. 2019;10:1382. doi:10. 3389/fmicb.2019.01382
60. Kim JA, Bayo J, Cha J, et al. Investigating the probiotic characteristics of four microbial strains with potential application in feed industry. PLoS One. 2019;14(6):e0218922. doi:10.1371/journal.pone.0218922
61. Wan G, Wang L, Zhang G, et al. Effects of probiotics combined with early enteral nutrition on endothelin-1 and C-reactive protein levels and prognosis in patients with severe traumatic brain injury. J Int Med Res. 2019;48(3):1-9. doi:10.1177/0300060519888112
62. Tzikos G, Tsalkatidou D, Stavrou G, et al. A four-probiotic regime to reduce surgical site infections in multi-trauma patients. Nutrients. 2022;14(13):2620. doi:10.3390/nu14132620
63. Pagkou D, Kogias E, Foroglou N, Kotzampassi K. Probiotics in traumatic brain injury: new insights into mechanisms and future perspectives. J Clin Med. 2024;13(15):4546. doi:10.3390/jcm13154546
64. Tan M, Zhu JC, Du J, Zhang LM, Yin HH. Effects of probiotics on serum levels of Th1/Th2 cytokine and clinical outcomes in severe traumatic brain-injured patients: a prospective randomized pilot study. Crit Care. 2011;15(6):R290. doi:10.1186/cc10579
65. Usai-Satta P, Lai M, Oppia F, Cabras F. Effects of prokinetics on the digestive tract. Curr Rev Clin Exp Pharmacol. 2022;17(3):161-165. doi:10.2174/2772432816666210805125813
66. Camilleri M, Atieh J. New developments in prokinetic therapy for gastric motility disorders. Front Pharmacol. 2021;12:711500. doi:10.3389/fphar.2021.711500
67. Roe NA, Sakaan S, Swanson H, Twilla JD. Evaluation of prokinetic agents used in the treatment of gastroparesis. J Drug Assess. 2017;6(1):6-9. doi:10. 1080/21556660.2016.1278546
68. Hawkyard C V, Koerner RJ. The use of erythromycin as a gastrointestinal prokinetic agent in adult critical care: benefits versus risks. J Antimicrob Chemother. 2007;59(3):347-358. doi:10.1093/jac/dkl537
69. Yang YJ, Bang CS, Baik GH, et al. Prokinetics for the treatment of functional dyspepsia: Bayesian network meta-analysis. BMC Gastroenterol. 2017;17(1):83. doi:10.1186/s12876-017-0639-0
70. Quigley EMM. Prokinetics in the management of functional gastrointestinal disorders. J Neurogastroenterol Motil. 2015;21(3):330-336. doi:10.1007/s11894-017-0593-6
71. Hiyama T, Yoshihara M, Tanaka S, Haruma K, Chayama K. Effectiveness of prokinetic agents against diseases external to the gastrointestinal tract. J Gastroenterol Hepatol. 2009;24(4):537-546. doi:10.1111/j.1440-1746.2009. 05780.x
72. Baradari AG, Khajavi MR, Firouzian A, et al. Effects of combined prokinetic administration on gastric emptying in critically ill patients. Arab J Gastroenterol. 2017;18(1):30-34. doi:10.1016/j.ajg.2017.01.007
73. Parthasarathy G, Ravi K, Camilleri M, et al. Effect of neostigmine on gastroduodenal motility in patients with suspected gastrointestinal motility disorders. Neurogastroenterol Motil. 2015;27(12):1736-1746. doi:10.1111/nmo.12669
74. Jayarajah U, Yapa K, Ranaweera K, Rahuman A, Perera P, Weerasekara D. Successful use of neostigmine for resistant gastroparesis following distal gastrectomy: a case report. Int J Surg Case Rep. 2023;106:108166. doi:10.1016/j.ijscr.2023.108166
75. Tonini M, Cipollina L, Poluzzi E, Crema F, Corazza GR, De Ponti F. Review article: clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics. Aliment Pharmacol Ther. 2004;19(4):379-390. doi:10.1111/j.1365-2036.2004. 01867.x
76. Makkar JK, Gauli B, Jain K, Jain D, Batra YK. Comparison of erythromycin versus metoclopramide for gastric feeding intolerance in patients with traumatic brain injury: a randomized double-blind study. Saudi J Anaesth. 2016;10:308-313. doi:10.4103/1658-354X.174902
77. Lewis K, Alqahtani Z, Mcintyre L, et al. The efficacy and safety of prokinetic agents in critically ill patients receiving enteral nutrition: a systematic review and meta-analysis of randomized trials. Crit Care. 2016;20(1):259. doi:10.1186/s13054-016-1441-z
78. Nursal T, Erdogan B, Noyan T, Cekinmez M, Gülşen B, Bilgin N. The effect of metoclopramide on gastric emptying in traumatic brain injury. J Clin Neurosci. 2007;14(5):344-348. doi:10.1016/j.jocn.2005.11.011
79. Peng R, Li H, Yang L, et al. The efficacy and safety of prokinetics in critically ill adults receiving gastric feeding tubes: a systematic review and meta-analysis. PLoS One. 2021;16(1):e0245317. doi:10.1371/journal.pone.0245317
80. Davani-Davari D, Negahdaripour M, Karimzadeh I, et al. Prebiotics: definition, types, sources, mechanisms, and clinical applications. Foods. 2019;8(3):92. doi:10.3390/foods8030092
81. Bamigbade GB, Subhash AJ, Kamal-Eldin A, Nyström L, Ayyash M. An updated review on prebiotics: insights on potentials of food seeds waste as source of potential prebiotics. Molecules. 2022;27:5947. doi:10.3390/molecules27185947
82. Bedu-Ferrari C, Biscarrat P, Langella P, Cherbuy C. Prebiotics and the human gut microbiota: from breakdown mechanisms to the impact on metabolic health. Nutrients. 2022;14:2096. doi:10.3390/nu14102096
83. Sankarganesh P, Bhunia A, Kumar AG, Babu S, Gopukumar ST, Lokesh E. Short-chain fatty acids (SCFAs) in gut health: implications for drug metabolism and therapeutics. Med Microecol. 2025;25:100139. doi:10. 1016/j.medmic.2025.100139
84. Markowiak P, Slizewska K. Effects of probiotics, prebiotics, and synbiotics on human health. Nutrients. 2017;9(9):1021. doi:10.3390/nu9091021
85. Meena KK, Joshi M, Gupta L, Meena S. Comprehensive insights into postbiotics: bridging the gap to real-world application. Food Nutr. 2025; 1(2):100024. doi:10.1016/j.fnutr.2025.100024
86. Luo C, Li S, Chen T. Editorial: The role of probiotics, postbiotics, and microbial metabolites in preventing and treating chronic diseases, volume II. Front Cell Infect Microbiol. 2024;14:1442855. doi:10.3389/fcimb.2024.1442855
87. Kim KO, Gluck M. Fecal microbiota transplantation: an update on clinical practice. Clin Endosc. 2019;52:137-143. doi:10.5946/CE.2019.009
88. Yu J, Chen YX, Wang JW, Wu HT. Research progress on the relationship between traumatic brain injury and brain-gut-microbial axis. Ibrain. 2024;10:477-487. doi:10.1002/ibra.12153
89. Davis BT, Chen Z, Islam MBAR, Timken ME, Procissi D, Schwulst SJ. Post-injury fecal microbiome transplant decreases lesion size and neuroinflammation in traumatic brain injury. Shock. 2022;58(4):287-294. doi:10.1097/SHK.0000000000001979